Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
The purpose of this research study is to learn if giving rituximab, the study drug, right into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.
Non Hodgkin Lymphoma
DRUG: Rituximab
Ability to deliver greater than 80% of planned doses, Percentage of planned doses administered for planned accrual, 28 months|Related Grade 3 or higher non-hematological toxicity, Number of related grade 3 or higher non-hematological toxicities, 28 months
The purpose of this research study is to learn if giving rituximab, the study drug, right into the spinal canal along with chemotherapy drugs like methotrexate is possible and safe.